¼±Åà - È»ìǥŰ/¿£ÅÍŰ
´Ý±â - ESC
KMLE °Ë»ö
°Ë»ö ¼³Á¤
¿Â¶óÀÎ ÀÇÇмÀû
ÀÇÇпë¾î »çÀü
ÀÇÇоà¾î
ÀÇÇлçÀü
ÇÑ¿µ/¿µÇÑ»çÀü
¿µ¿µ»çÀü
»çÀÌÆ® ¼Ò°³
Àç°Ë»ö
"È¿"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
blow back effect
µÞ¹Ù¶÷È¿°ú, ÈÄdzȿ°ú
bound coagulase
±Õü°áÇÕÇ÷ÀåÀÀ°íÈ¿¼Ò
brancher enzyme
°¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
branching enzyme
°¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
breathing ferment
È£Èí¹ßÈ¿¼Ò
clinical efficacy
ÀÓ»óÈ¿´É
coagulase
Ç÷ÀåÀÀ°íÈ¿¼Ò
coenzyme
º¸Á¶È¿¼Ò
cohort effect
ÄÚȣƮȿ°ú
colipase
Áö¹æºÐÇØº¸Á¶È¿¼Ò, ÄÚ¸®ÆÄ¾ÆÁ¦
collagenase
¾Æ±³ÁúºÐÇØÈ¿¼Ò, Äݶó°ÕºÐÇØÈ¿¼Ò
collective effective dose
Áý´ÜÀ¯È¿¼±·®
combined effect
º´¿ëÈ¿°ú
committed effective dose
¿¹Å¹À¯È¿¼±·®
carbamoyltransferase
Ä«¸£¹Ù¸ðÀÏÀüÀÌÈ¿¼Ò
ÀÌÀü
´ÙÀ½
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
kininase
Ű´ÑÈ¿¼Ò
keratinase
°¢ÁúºÐÇØÈ¿¼Ò
lipase
ÁöÁúºÐÇØÈ¿¼Ò
lactase
Á¥´çºÐÇØÈ¿¼Ò
metalloproteinase
±Ý¼Ó´Ü¹éºÐÇØÈ¿¼Ò
restriction map
Á¦ÇÑÈ¿¼ÒÁöµµ
nucleotidase
´ºÅ¬·¹¿ÀƼµåºÐÇØÈ¿¼Ò
oxidase
»êÈÈ¿¼Ò
plasmin
Çö󽺹Î, ¼¶À¯¼Ò¿ëÇØÈ¿¼Ò
peroxidase
°ú»êÈÈ¿¼Ò
phosphatase
ÀλêºÐÇØÈ¿¼Ò
phosphorylase
ÀλêÈÈ¿¼Ò
peptidase
ÆéƼµåºÐÇØÈ¿¼Ò
proteinase
´Ü¹éºÐÇØÈ¿¼Ò
protease
´Ü¹éºÐÇØÈ¿¼Ò
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
bound coagulase
±Õü°áÇÕÇ÷ÀåÀÀ°íÈ¿¼Ò
branching enzyme
°¡ÁöÄ¡±âÈ¿¼Ò, ºÐÁöÈ¿¼Ò
breathing ferment
È£Èí¹ßÈ¿¼Ò
bridle effect
°í»ßÈ¿°ú, Á¦¾îÈ¿°ú
carboxypeptidase
Ä«¸£º¹½ÃÆéƼµåºÐÇØÈ¿¼Ò
chitinase
ŰƾºÐÇØÈ¿¼Ò
coagulase
Ç÷ÀåÀÀ°íÈ¿¼Ò
coenzyme
º¸Á¶È¿¼Ò
colipase
Áö¹æºÐÇØº¸Á¶È¿¼Ò, ÄÚ¸®ÆÄ¾ÆÁ¦
collagenase
¾Æ±³ÁúºÐÇØÈ¿¼Ò
convertase
Àüȯȿ¼Ò
cytozyme
¼¼Æ÷È¿¼Ò
carbonic anhydrase inhibitor
ź»êÅ»¼öÈ¿¼Ò¾ïÁ¦Á¦
carrier effect
¿î¹Ýüȿ°ú
carry-over effect
ÀÜÈ¿
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ELBF=£¾effective liver blood flow
À¯È¿¼º °£Ç÷·ù.
ELBF=£¾effective liver blood flow
À¯È¿ °£Ç÷·ù.
EPNDB =effective perceived noise level
½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§, ½ÇÁ¦°¨°¢¼ÒÀ½
EPNDB=ÊÝeffective perceived noise level
½ÇÈ¿°¨¼ö¼ÒÀ½·¹º§.
ERPF => effective renal plasma flow
À¯È¿½ÅÇ÷ÀåÀ¯Åë·®
ERPF=£¾effective renal plasma flow
À¯È¿½ÅÇ÷·ù·®.
Fahraeus-Lindqvist effect
ÆÄ·¹¿ì½º-¸°Äûºñ½ºÆ® È¿°ú(üùÍý)
Fenn effect
Ææ È¿°ú(üùÍý)
GDH= glycerophosphate dehydrogenase
±Û¸®¼¼·ÎÀλêÅ»¼ö¼ÒÈ¿¼Ò.
GOD= glucose oxidase
Æ÷µµ´ç»êÈ È¿¼Ò.
GOT= glutamic oxalacetic transaminase
±Û·çŸ¹Î¿Á»ìÃÊ»êÀüÀÌÈ¿¼Ò.
Gelatinase
Á©¶óƾºÐÇØÈ¿¼Ò(ÝÂú°ý£áÈ)
Gibbs effect
±é½º È¿°ú
Glucose-6-phosphate dehydrogenase
±Û·çÄÚ¿À½º-6-Àλê(×òß«)Å»¼ö¼ÒÈ¿¼Ò(÷â©áÈý£áÈ)
Glutaminase
±Û·çŽ»êºÐÇØÈ¿¼Ò(ÝÂú°ý£áÈ)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
enzymes
È¿¼Ò(ý£áÈ)
enzymes
È¿¼Ò(ý£áÈ)
enzyme
È¿¼Ò(ý£áÈ).
enzyme-antibody conjugate
È¿¼Ò-Ç×ü ¹èÇÕü
ase =enzyme
È¿¼Ò.
enzymatic defect
È¿¼Ò°á¼Õ(Áõ)(ý£áÈÌÀáßñø).
enzyme deficiency
È¿¼Ò°áÇÌ(Áõ)
enzymopenic
È¿¼Ò°áÇÌÀÇ.
enzymoprivic
È¿¼Ò°áÇÌÁõÀÇ.
enzymic antagonist
È¿¼Ò±æÇ×Á¦.
enzyme glaucoma
È¿¼Ò³ì³»Àå
enzymuria
È¿¼Ò´¢Áõ(¡èññø).
enzyme-multiplied/mediated immunoassay
È¿¼Ò´ÙÁß/¸Å°³ ¸é¿ªÃøÁ¤(¹ý)
zymoprotein
È¿¼Ò´Ü¹éÁú(ý£áÈÓ±ÛÜòõ).
enzyme immunoassay
È¿¼Ò¸é¿ªÃøÁ¤(¹ý)
ÀÌÀü
´ÙÀ½
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
antioxidase
Ç×»êÈÈ¿¼Ò(ù÷ß«ûùý£áÈ).
antiprotease
Ç״ܹéÈ¿¼Ò(ù÷Ó±ÛÜý£áÈ)
antitoxemic effect
Ç×µ¶Ç÷ÁõÈ¿°ú.
antitussive effect
ÁøÇØÈ¿°ú(òåú¦üùÍý).
antiyeast substance
Ç×È¿¸ð¹°Áú.
apoenzyme
¾ÆÆ÷È¿¼Ò.
apoenzyme
¾ÆÆ÷È¿¼Ò
apoenzyme portion
¾ÆÆ÷È¿¼Ò ºÎºÐ
arginine decarboxylase reagent
¾Æ¸£±â´ÑŻī¸£º¹½ÇÈ¿¼Ò<--µ¥Ä«¸£º¹½Ç¶óÁ¦
arginosuccinic lyase
¾Æ¸£±â´ÑÈ£¹Ú»ê¸®¾ÆÁ¦<--Àý´ÜÈ¿¼Ò>
artificial age hardening
Àΰø½ÃÈ¿°æÈ(ìÑÍïãÁüùÌãûù).
ascosporogenous yeast
À¯Æ÷ÀÚÈ¿¸ð(êóøàíý£Ù½).
ascosporogenous yeast
À¯Æ÷ÀÚÈ¿¸ð(êóøàíý£Ù½).
ase =enzyme
È¿¼Ò.
assay
Á¤·®, ¿ª°¡°ËÁ¤, È¿·Â°ËÁ¤.
ÀÌÀü
´ÙÀ½
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
12
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
enzyme analogue
È¿¼ÒÀ¯»çü(ý£áÈëºÞÄô÷)
proenzyme
È¿¼ÒÀü±¸Ã¼(ý£áÈîñÏÌô÷)
enzyme electrode
È¿¼ÒÀü±Ø(ý£áÈï³Ð¿)
enzymoelectrophoresis
È¿¼ÒÀü±â¿µµ¿(ý£áÈï³Ñ¨ç¶ÔÑ)
enzyme species
È¿¼ÒÁ¾(ý£áÈðú)
enzyme therapy
È¿¼ÒÄ¡·á (ý£áÈö½Öû)
enzyme-specific electrode
È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
enzyme specificity
È¿¼ÒƯÀ̼º(ý£áÈ÷åì¶àõ)
enzyme labeling
È¿¼ÒÇ¥Áö(ý£áÈøöò½)
enzymology
È¿¼ÒÇÐ(ý£áÈùÊ)
concentration of enzymatic activity
È¿¼ÒȰ¼º ³óµµ(ý£áÈüÀàõÒØÓø)
efficiency
È¿À²(üù×Ë)
ÀÌÀü
´ëÇÑ»ýÈÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
coenzyme II
"º¸È¿¼Ò(ÜÍý£áÈ) II,(ÔÒ) NADP"
coenzyme A
º¸È¿¼Ò(ÜÍý£áÈ) A
coenzyme B12
"º¸È¿¼Ò(ÜÍý£áÈ) B12, (ÔÒ) cobamide"
coenzyme-coupled reactions
º¸È¿¼Ò(ÜÍý£áÈ)¦Áö¿ò ¹ÝÀÀ
coenzyme F
"º¸È¿¼Ò(ÜÍý£áÈ) F, (ÔÒ) folate coenzyme"
coenzyme M
"º¸È¿¼Ò(ÜÍý£áÈ) M, (ÔÒ) 2,2'-dithiodiethanesulfonic acid :"
coenzyme Q
º¸È¿¼Ò(ÜÍý£áÈ) Q
coenzyme Q-cytochrome c reductase complex
º¸È¿¼Ò(ÜÍý£áÈ) Q¡¤»çÀÌÅäÅ©·Ò C ¸®´ÚÅ×À̽º (ÔÒ) complex III
coenzyme R
"º¸È¿¼Ò(ÜÍý£áÈ) R, (ÔÒ) biotin"
cold-sensitive enzyme
³Ã¹Î°¨ È¿¼Ò(Ò²ÚÂÊïý£áÈ)
clod-stable enzyme
³Ã¾ÈÁ¤ È¿¼Ò(Ò²äÌïÒý£áÈ)
Compton effect
ÄÞÅæ È¿°ú(üùÍý)
condensing enzyme
ÃàÇÕÈ¿¼Ò(õêùêý£áÈ)
conjugated enzyme
Á¢ÇÕÈ¿¼Ò(ïÈùêý£áÈ)
constitutive enzyme
±¸¼ºÈ¿¼Ò(ϰà÷ý£áÈ)
ÀÌÀü
´ÙÀ½
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
13
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
radiation effect
¹æ»ç¼±È¿°ú
radio-frequency thermal effect
°íÁÖÆÄ¿È¿°ú
respiratory dead space
È£Èí¼º¹«È¿°ø°£
reverse piezoelectric effect
¿ª¾ÐÀüÈ¿°ú
RF antennae effect
°íÁ֯ľÈÅ׳ªÈ¿°ú
shielding effect
Â÷ÆóÈ¿°ú
siphonage effect
½ÎÀÌÆùÈ¿°ú
spatial presaturation effect
°ø°£ÀüÆ÷ÈÈ¿°ú
spin phase effect
½ºÇÉÀ§»óÈ¿°ú
T1 shortening effect
T1´ÜÃàÈ¿°ú
T2 shortening effect
T2´ÜÃàÈ¿°ú
utility
¼Òºñ·®, À¯¿ë¼º, È¿¿ë
volume averaging effect
¿ëÀûÆò±ÕÈÈ¿°ú
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú :
5
ÆäÀÌÁö:
4
ÄÚµå
¿µ¹®
ÇѱÛ
R83.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
R84.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
R85.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
R86.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
R87.0
Abnormal level of enzymes
ÀÌ»ó È¿¼Ò ¼öÄ¡
ÀÌÀü
´ÙÀ½
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
¼³¸í
converting enzyme
Àüȯ È¿¼Ò
cost-effectiveness
ºñ¿ë È¿À²
cryptococcal meningitis
È¿¸ð±Õ¼º ³ú¸·¿°
Cryptococcosis
È¿¸ð±ÕÁõ, Å©¸³ÅäÄÚÄ¿½º º´, Å©¸³ÅäÄÛÄí½ºÁõ
1. Áø±Õ·ùÀÇ ÀÏÁ¾ÀÎ Cri
Cryptococcus dermitidis
°¡¼º È¿¸ð±Õ
Cryptococcus hominis
³ó¾ç È¿¸ð±Õ, Å©¸³ÅäÄÛÄí½º È£¹Ì´Ï½º
curative dose
ġȿ·®
cytochrome oxidase test
»çÀÌÅäÅ©·Ò »êÈ È¿¼Ò °Ë»ç
cytohydrolist
¼¼Æ÷¸· °¡¼öºÐÇØ È¿¼Ò
¼¼Æ÷ º®À» °¡¼öºÐÇØ¿¡ ÀÇÇÏ¿© ÆÄ±«ÇÏ´Â È¿¼Ò.
cytopathogenic effect
¼¼Æ÷ º¯¼º Çö»ó, ¼¼Æ÷ º´º¯ È¿°ú
dead space
»ç°, ¹«È¿ °ø°£
decarboxylation
Żī¸£º¹½Ç ¹ÝÀÀ, Żī¸£º¹½Ç È¿¼Ò ¹ÝÀÀ, Żī¸£º¹½Ç ÀÛ¿ë
Deelman`s effect
µ¨¸¸ È¿°ú
dehydrase
Å»¼ö¼Ò È¿¼Ò
Å»¼ö¼Ò È¿¼Ò¿Í Å»¼ö È¿¼Ò ¾çÀÚ¿¡ »ç¿ëµÇ¾ú´ø ¿¾ ¿ë¾î.
deiodinase
Å»À̿ ȿ¼Ò
ÀÌÀü
´ÙÀ½
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú :
15
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
Doppler Lidar System
µµÇ÷¯ È¿°ú¸¦ ÀÌ¿ëÇÑ ±¤ÇÐ½Ä ¼Óµµ°è
Doppler effect
µµÇ÷¯ È¿°ú
ED
effectove dpse.(¾àÀÇ)À¯È¿·®;environmental disruption ȯ°æ ÆÄ±«
EER
energy efficiency ratio(Àü)¿¡³ÊÁö È¿À²ºñ o
EHP
effective horse power À¯È¿ ¸¶·Â;electrical horse power Àü±â ¸¶·Â
EPNdB
effective perceived noise decibels °¨°¢ ¼ÒÀ½ È¿°ú µ¥½Ãº§
G.T.C.
good till canceled (countermanded) Ãë¼ÒÇÒ ¶§±îÁö À¯È¿
Halaphone
ÇÒ¶óÆù(ÀüÀÚ À½Çâ(È¿°ú) ÀåÄ¡(¾Ç±â);¿ÀÄɽºÆ®¶ó ¿¬ÁÖ Áß¿¡ °®°¡Áö À½Çâ È¿°ú¸¦ ´õÇØ ÁÖ´Â
IU
international unit (»ý)ºñŸ¹Î·®È¿°ú ÃøÁ¤¿ë);±¹Á¦ ´ÜÀ§
Lasparaginase
¿¤ ¾Æ½º¶óÆÄ±â³ª¾ÆÁ¦(¹éÇ÷º´ Ä¡·á¿ë È¿¼Ò)
MOSFET
±Ý¼Ó »êȸ· ¹ÝµµÃ¼ Àü°è È¿°ú Æ®·£Áö½ºÅÍ
NAD
nicotinamide-adenine dinucleotide(»ýÈ)´ÏÄÚÆ¾ ¾Æ¹Ìµå ¾Æµ¥´Ñ µð´©Å¬·¹¿ÀƼµå(º¸Á¶È¿¼ÒÀÇ ÀÏÁ¾)no appreciable disease;nothing abnormal discovered
Ovonic
¿Àºê½Å½ºÅ° È¿°ú;¿Àº¸´Ð ÀåÄ¡
RNA polymerase
RNA Æ÷¸®¸Þ¶óÁ¦(¸®º¸ÇÙ»ê ÇÕ¼ºÈ¿¼Ò)
RNA replicase
RNA ·¹Çø®Ä«Á¦(RNAÇÕ¼ºÈ¿¼Ò)
ÀÌÀü
´ÙÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
Á¦Ç°¸í
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÇÑÀÚ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÀÌÀü
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
ÄÚµå
¿µ¹®
ÇѱÛ
ÀÌÀü
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
¼³¸í
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú:
0
ÆäÀÌÁö:
4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå
¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
ÀÌÀü
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú :
0
ÆäÀÌÁö:
4
¿µ¹®
ÇѱÛ
ÀÌÀü
ÅëÇÕ°Ë»ö ¿Ï·á
ÀÌÀü
´ÙÀ½